Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer

被引:44
|
作者
Poettgen, Christoph [1 ]
Theegarten, Dirk [5 ]
Eberhardt, Wilfried [2 ]
Levegruen, Sabine [1 ]
Gauler, Thomas [2 ]
Krbek, Thomas
Stamatis, Georgios [6 ]
Teschler, Helmut [7 ]
Kuehl, Hilmar [3 ]
Bockisch, Andreas [4 ]
Stuschke, Martin [1 ]
机构
[1] Univ Duisburg Essen, Dept Radiotherapy, DE-45122 Essen, Germany
[2] Univ Duisburg Essen, Dept Intenal Med Canc Res, DE-45122 Essen, Germany
[3] Univ Duisburg Essen, Dept Diagnost & Intervent Radiol, DE-45122 Essen, Germany
[4] Univ Duisburg Essen, Dept Nucl Med, DE-45122 Essen, Germany
[5] Univ Duisburg Essen, Inst Pathol & Neuropathol, DE-45122 Essen, Germany
[6] Univ Duisburg Essen, Dept Thorac Surg, DE-45122 Essen, Germany
[7] Univ Duisburg Essen, Dept Pulmonol, DE-45122 Essen, Germany
关键词
chemoradiotherapy; dual-modality PET/CT; locally advanced non-small cell lung cancer; macrophage infiltration; neoadjuvant;
D O I
10.1159/000134474
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Prediction of histopathological response with PET/CT scans after neoadjuvant chemoradiotherapy is limited by confounding factors which have been evaluated in this analysis. Methods: F-18-2-fluoro-2-deoxy-D-glucose (FDG)-PET/CT findings [standard uptake value (SUV), residual tumor volume] were correlated with histopathological parameters of the resection specimens (tumor cell density, necrosis, scar, macrophage infiltration) in patients with locally advanced non-small cell lung cancer (stage IIIA/IIIB) after neoadjuvant induction chemotherapy (platinum-based doublet) and concurrent chemoradiotherapy (cisplatin/vinorelbine/ 45 Gy). Results: Sixty patients [40 male/20 female, median age 56 years (34-78)] completed induction therapy, 46 patients (stage IIIA/IIIB: 16/30; squamous cell carcinoma 41%, adenocarcinoma 48%, large cell carcinoma 11%) were resected. Pathologic complete response of the primary tumor was observed in 19 patients (41%) with a broad range of SUVmean (0.4-9.8, mean 3.0) after neoadjuvant therapy. A high rate of histopathological complete remissions (44%) was observed in tumors with a postinduction SUV > 2.5 and volumes larger than the median (7.9 cm(3)) before resection. SUVmean was positively correlated with the macrophage score (r = 0.39, p = 0.007) and tumor cell density (r = 0.32, p = 0.03). Conclusions: These observations suggest that postinduction FDG uptake should be interpreted with caution in larger residual tumor volumes, since high SUV levels may be due to macrophage infiltration and not viable tumor tissue. Copyright (c) 2008 S. Karger AG, Basel.
引用
收藏
页码:316 / 323
页数:8
相关论文
共 50 条
  • [21] Neoadjuvant immunology therapy in patients with non-small cell lung cancer and chronic obstructive pulmonary disease
    Chang, Qing
    Li, Jiaqi
    Zhu, Yan
    Qiang, Huiping
    Lu, Haijiao
    Shen, Yinchen
    Wang, Shuyuan
    Qian, Jialin
    Chu, Tianqing
    JOURNAL OF THORACIC DISEASE, 2024, 16 (11) : 7546 - 7560
  • [22] Local failure after radical radiotherapy of non-small cell lung cancer in relation to the planning FDG-PET/CT
    Kandi, M.
    Hoffmann, L.
    Moeller, D. Sloth
    Schmidt, H. H.
    Knap, M. M.
    Khalil, A. A.
    ACTA ONCOLOGICA, 2018, 57 (06) : 813 - 819
  • [23] Comparing Outcomes of Neoadjuvant and Adjuvant Chemotherapy in Non-Small Cell Lung Cancer
    Sharma, Sandhya
    Bista, Amir
    Joshi, Abhash
    Charles, Kevin
    Lash, Bradley
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S571 - S571
  • [24] The Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer
    Guven, Deniz Can
    Sahin, Taha Koray
    Kilickap, Saadettin
    CANCERS, 2024, 16 (01)
  • [25] Neoadjuvant chemotherapy in early-stage non-small cell lung cancer
    Salva, Francesc
    Felip, Enriqueta
    TRANSLATIONAL LUNG CANCER RESEARCH, 2013, 2 (05) : 398 - 402
  • [26] Neoadjuvant Radiotherapy/Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer
    Yalman, Deniz
    BALKAN MEDICAL JOURNAL, 2015, 32 (01) : 1 - 7
  • [27] Safety and feasibility of minimally invasive lobectomy after neoadjuvant immunotherapy for non-small cell lung cancer
    Mathey-Andrews, Camille
    McCarthy, Meghan
    Potter, Alexandra L.
    Beqari, Jorind
    Wightman, Sean C.
    Liou, Douglas
    Raman, Vignesh
    Yang, Chi -Fu Jeffrey
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2023, 166 (02) : 347 - +
  • [28] Comparative evaluation of staging algorithms proven N2 non-small cell lung cancer treated by lung resection after neoadjuvant therapy
    Isgorucu, Ozgur
    Citak, Necati
    Acikmese, Baris
    Fener, Neslihan Akalin
    Buyukkale, Songul
    Sayar, Adnan
    TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2022, 30 (03): : 372 - 380
  • [29] Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Trends and Surgical Outcomes in a Regionalized Network
    Pilon, Yohann
    Rokah, Merav
    Seitlinger, Joseph
    Sepesi, Boris
    Rayes, Roni F.
    Cools-Lartigue, Jonathan
    Najmeh, Sara
    Sirois, Christian
    Mulder, David
    Ferri, Lorenzo
    Abdulkarim, Bassam
    Ezer, Nicole
    Fraser, Richard
    Camilleri-Broet, Sophie
    Fiset, Pierre-Olivier
    Wong, Annick
    Sud, Shelly
    Langleben, Adrian
    Agulnik, Jason
    Pepe, Carmela
    Shieh, Benjamin
    Hirsh, Vera
    Ofiara, Linda
    Owen, Scott
    Spicer, Jonathan D.
    CLINICAL LUNG CANCER, 2024, 25 (03) : e133 - e144.e4
  • [30] Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable Non-Small Cell Lung Cancer
    Zhang, Y.
    Zeng, L.
    Zhang, X.
    Zhou, Y.
    Zhang, B.
    Jiang, W.
    Yang, N.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1014 - S1015